Annual CFF
$140.13 M
-$14.21 M-9.21%
December 31, 2023
Summary
- As of February 7, 2025, RXRX annual cash flow from financing activities is $140.13 million, with the most recent change of -$14.21 million (-9.21%) on December 31, 2023.
- During the last 3 years, RXRX annual CFF has fallen by -$106.00 million (-43.07%).
- RXRX annual CFF is now -69.44% below its all-time high of $458.54 million, reached on December 31, 2021.
Performance
RXRX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$16.46 M
-$246.66 M-93.74%
September 30, 2024
Summary
- As of February 7, 2025, RXRX quarterly cash flow from financing activities is $16.46 million, with the most recent change of -$246.66 million (-93.74%) on September 30, 2024.
- Over the past year, RXRX quarterly CFF has increased by +$2.56 million (+18.46%).
- RXRX quarterly CFF is now -96.45% below its all-time high of $463.70 million, reached on June 30, 2021.
Performance
RXRX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$374.14 M
-$37.30 M-9.07%
September 30, 2024
Summary
- As of February 7, 2025, RXRX TTM cash flow from financing activities is $374.14 million, with the most recent change of -$37.30 million (-9.07%) on September 30, 2024.
- Over the past year, RXRX TTM CFF has increased by +$222.03 million (+145.97%).
- RXRX TTM CFF is now -46.98% below its all-time high of $705.60 million, reached on June 30, 2021.
Performance
RXRX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
RXRX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -9.2% | +18.5% | +146.0% |
| 3 y3 years | -43.1% | -88.8% | +142.4% |
| 5 y5 years | +16.4% | -88.8% | +142.4% |
RXRX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -69.4% | at low | -93.7% | +756.5% | -18.4% | >+9999.0% |
| 5 y | 5-year | -69.4% | +16.4% | -96.5% | +248.4% | -47.0% | >+9999.0% |
| alltime | all time | -69.4% | +16.4% | -96.5% | +248.4% | -47.0% | >+9999.0% |
Recursion Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $16.46 M(-93.7%) | $374.14 M(-9.1%) |
| Jun 2024 | - | $263.12 M(+1793.4%) | $411.44 M(+170.5%) |
| Mar 2024 | - | $13.90 M(-82.8%) | $152.11 M(+8.5%) |
| Dec 2023 | $140.13 M(-9.2%) | $80.66 M(+50.0%) | $140.13 M(-32.2%) |
| Sep 2023 | - | $53.77 M(+1319.7%) | $206.73 M(+33.1%) |
| Jun 2023 | - | $3.79 M(+97.0%) | $155.30 M(+0.7%) |
| Mar 2023 | - | $1.92 M(-98.7%) | $154.18 M(-0.1%) |
| Dec 2022 | $154.34 M | $147.26 M(+6201.1%) | $154.34 M(+1318.0%) |
| Sep 2022 | - | $2.34 M(-12.4%) | $10.88 M(-527.4%) |
| Jun 2022 | - | $2.67 M(+28.0%) | -$2.55 M(-100.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $2.08 M(-45.1%) | $458.49 M(-0.0%) |
| Dec 2021 | $458.54 M(+86.3%) | $3.80 M(-134.2%) | $458.54 M(-1.3%) |
| Sep 2021 | - | -$11.10 M(-102.4%) | $464.78 M(-34.1%) |
| Jun 2021 | - | $463.70 M(>+9900.0%) | $705.60 M(+191.2%) |
| Mar 2021 | - | $2.13 M(-78.7%) | $242.27 M(-1.6%) |
| Dec 2020 | $246.13 M(+104.4%) | - | - |
| Dec 2020 | - | $10.04 M(-95.6%) | $246.13 M(+4.3%) |
| Sep 2020 | - | $229.72 M(>+9900.0%) | $236.10 M(+3601.2%) |
| Jun 2020 | - | $382.00 K(-93.6%) | $6.38 M(+6.4%) |
| Mar 2020 | - | $6.00 M | $6.00 M |
| Dec 2019 | $120.41 M | - | - |
FAQ
- What is Recursion Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals annual CFF year-on-year change?
- What is Recursion Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals quarterly CFF year-on-year change?
- What is Recursion Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals TTM CFF year-on-year change?
What is Recursion Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of RXRX is $140.13 M
What is the all time high annual CFF for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high annual cash flow from financing activities is $458.54 M
What is Recursion Pharmaceuticals annual CFF year-on-year change?
Over the past year, RXRX annual cash flow from financing activities has changed by -$14.21 M (-9.21%)
What is Recursion Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of RXRX is $16.46 M
What is the all time high quarterly CFF for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high quarterly cash flow from financing activities is $463.70 M
What is Recursion Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, RXRX quarterly cash flow from financing activities has changed by +$2.56 M (+18.46%)
What is Recursion Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of RXRX is $374.14 M
What is the all time high TTM CFF for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high TTM cash flow from financing activities is $705.60 M
What is Recursion Pharmaceuticals TTM CFF year-on-year change?
Over the past year, RXRX TTM cash flow from financing activities has changed by +$222.03 M (+145.97%)